Immunotherapy in Gastro-Esophageal Cancers

Hira Shaikh, Amir Kamran, Dulabh K Monga, Immunotherapy in gastroesophageal cancers: Current state and future directions, 2021 Mar;27(2):395-404.

J. Ferlay, I. Soerjomataram, R. Dikshit et al., “Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012, International Journal of Cancer, vol. 136, no. 5, pp. E359–E386, 2015.

Konstantinos Kamposioras , Panagiotis Ntellas, Michail Nikolaou, Theodora Germetaki, et al.Immunotherapy Efficacy in the Initial Lines of Treatment in Advanced Upper Gastrointestinal Malignancies: A Systematic Review of the Literature 2021 Nov 16;5 (6) :pkab088.

Kumar V, Ramnarayanan K, Sundar R, Padmanabhan N, Srivastava S, Koiwa M, et al.. Single-cell atlas of lineage states, tumor microenvironment, and subtype-specific expression programs in gastric cancer. Cancer Discov (2022) 12(3):670–91.

Chen D, Zhang X, Li Z, Zhu B. Metabolic regulatory crosstalk between tumor microenvironment and tumor-associated macrophages. Theranostics (2021) 11(3):1016–30.

Zhao Y, Rahmy S, Liu Z, Zhang C, Lu X. Rational targeting of immunosuppressive neutrophils in cancer. Pharmacol Ther (2020) 212:107556

Xie MZ, Tang YP, Hu BL, Li KZ, Li JL, Liang XQ. Percentage of natural killer (NK) cells in peripheral blood is associated with prognosis in patients with gastric cancer: A retrospective study from a single center. Med Sci monitor Int Med J Exp Clin Res (2021) 27:e927464

Yilin Lin, Xiangxiang Jing, Zhihua Chen, Xiaoxian Pan, Duo Xu, Xiang Yu, Fengyun Zhong, Long Zhao, Changjiang Yang, Bo Wang, Shan Wang , Yingjiang Ye, Zhanlong Shen Histone deacetylase-mediated tumor microenvironment characteristics and synergistic immunotherapy in gastric cancer 2023 Aug 18;13(13):4574-4600.

A. Cimino-Mathews, J. B. Foote, and L. A. Emens, “Immune targeting in breast cancer,” Oncology, vol. 29, pp. 375–385, 2015.

M. Naseem et al. Outlooks on Epstein-Barr virus associated gastric cancer. Cancer Treat. Rev.(2018)

S.Y. Kim et al. Deregulation of immune response genes in patients with Epstein-Barr virus-associated gastric cancer and outcomes. Gastroenterology (2015)

Yue W, Zhu M, Zuo L, Xin S, Zhang J, Liu L, et al. Early Pattern of Epstein-Barr Virus Infection in Gastric Epithelial Cells by “Cell-in-cell”. Virol Sin. 2019; 34(3):253–261.

Qingfang Zhao, Liang Cao, Lulu Guan Immunotherapy for gastric cancer: dilemmas and prospect Briefings in Functional Genomics, Volume 18, Issue 2, March 2019

Kong L, Wang X, Teng F, Yu J: PD-L1 expression in human cancers and its association with clinical outcomes. Onco Targets Ther 9:5023-5039, 2016

Grierson P, Lim KH, Amin M. Immunotherapy in gastrointestinal cancers. J Gastrointest Oncol 2017;8(3):474–84.

Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21(10):1353–1365.

Shitara K, Ozguroglu M, Bang YJ, Di Bartolomeo M, Mandala M, Ryu MH, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018;392(10142):123–33.

Boku N. A phase 3 study of nivolumab (Nivo) in previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: updated results and subset analysis by pd-l1 expression (ATT RAC TION-02). Ann Oncol. 2017;28:v209–68.

Ready NE, Ott PA, Hellmann MD, Zugazagoitia J, Hann CL, Braud F, et al. Nivolumab monotherapy and nivolmab plus ipilimumab in recurrent small cell lung cancer: results from the CheckMate 032 ramdomized cohort. J Thocac Oncol. 2020;15(3):426–35

Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455– 65.

Segal NHAS, Brahmer JR, Maio M, Blake-Haskins A, Vasselli XL, Ibrahim RA, et al. Preliminary data from a multi-arm expan sion study of MEDI4736, an anti-PD-L1 antibody. J Clin Oncol. 2014;32:3002.

Keilholz U, Mehnert JM, Bauer S, Bourgeois H, Patel MR, Gravenor D, et al. Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN solid tumor trial. J immunother Cancer. 2019.

Bang EYRY-J, Van Cutsem E, Lee K-W, Wyrwicz L, Schenker M, Alsina M, Phase III. randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300. Ann Oncol. 2018;29(10):2052–60.

ClinicalTrials.gov: an efficacy study in gastric and gastroesopha geal junction cancer comparing ipilimumab versus standard of care immediately following first line chemotherapy. https ://clini caltrials.gov/ct2/show/NCT01585987. Accessed 17 May 2016.

Ralph C, Elkord E, Burt DJ, O’Dwyer JF, Austin EB, Stern PL, Hawkins RE, Thistlethwaite FC. Modulation of lymphocyte reg ulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma. Clin Cancer Res. 2010;16(5):1662–72.

Janjigian YY, Bendell J, Calvo E, Kim JW, Ascierto PA, Sharma P, Ott PA, Peltola K, Jaeger D, Evans J, De Braud F. CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer. J Clin Oncol. 2018;36(28):2836.

Teng F, Kong L, Meng X, et al. Radiotherapy combined with immune checkpoint blockade immunotherapy: Achievements and challenges. Cancer Lett 2015;365:23.

Alsina M, Moehler M, Lorenzen S. Immunotherapy of esophageal cancer: current status, many trials and innovative strategies. Oncol Res Treat. 2018; 41: 266–271.

ClinicalTrials.gov, Study evaluating the efficacy and safety with CAR-T for stomach cancer (EECSC). https ://clini caltr ials.gov/ct2/ show/NCT02725125. Accessed 23 Mar 2017.

Yang J, Li Z-H, Zhou J-J, Chen R-F, Cheng L-Z, Zhou Q-B, et al. Preparation and antitumor effects of nanovaccines with MAGE-3 peptides in transplanted gastric cancer in mice. Chin J Cancer. 2010;29(4):359–64.

Gilliam ADSA, Watson G. 17DT: an antigastrin immunogen for the treatment of gastrointestinal malignancy. Expert Opin Biol Ther. 2007;7(3):397–404.

Muro K, Bang Y-J, Shankaran V. Relationship between PD-L1 expression and clinical outcomes in patients (Pts) with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (Pembro; MK-3475) in KEYNOTE-012. J Clin Oncol 33, 2015 (suppl 3; abstr 3)

Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Ruschoff J, et al. Revised bethesda guidelines for hereditary non polyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96(4):261–8.

Shin DS, Zaretsky JM, Escuin-Ordinas H, Garcia-Diaz A,, et al. primary resistance to pd-1 blockade mediated by JAK1/2 mutations. Cancer Discov. 2017;7(2):188–201.